Lab M appoints new managing director

Ian Morris combines business and science skills

Lab M appoints new managing director

UK microbiological diagnostic product firm Lab M has appointed Ian Morris as managing director. Morris combines a science background with business experience at a senior level. He joined Lab M at the beginning of the year and is based at the company’s headquarters in Bury, Lancashire.

Morris’s scientific training is in chemistry and biology. He has a Diploma in Brewing (Dip.Brew) and is a Member of Institute of Food Science and Technology (MIFST).

Lab M provides a range of precise, rapid and dependable methodology for the detection, isolation and identification of micro-organisms.

You may also like

Analysis
Lab M adds Pinnacle pre-poured plates to prepared media offering

Lab M adds Pinnacle pre-poured plates to prepared media offering

The first Pinnacle products are for use in the food industry
Research & Development
Anton Paar launches new UNHT series for next-generation nanoindentation

Anton Paar launches new UNHT series for next-generation nanoindentation

Anton Paar introduces the new UNHT Series, a new generation of nanoindentation systems designed to deliver reliable results, faster workflows, and greater versatility across a wide range of materials
Analysis
Cochrane review links pharma payments to prescribing practices

Cochrane review links pharma payments to prescribing practices

A Cochrane review of 93 studies has linked pharmaceutical industry promotional activities with less appropriate prescribing and higher prescription costs, prompting renewed calls for stronger conflict-of-interest policies and greater transparency in the UK
Manufacturing
Patented device reinvents Solid Phase Extraction

Patented device reinvents Solid Phase Extraction

Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
You need to be a subscriber to read this article.
Click here to find out more.
Analysis
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)

Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)

Standardised cell systems can reduce biological variability, but robust potency testing must also demonstrate accuracy, precision and linearity. ICH Q2(R2) provides the framework to establish this analytical confidence
Regulatory
Leica Biosystems brings Tempus pathology products to Aperio AI Store

Leica Biosystems brings Tempus pathology products to Aperio AI Store

Expanding the Aperio AI Store gives researchers more ways to study cancer through AI-enabled tools within a connected digital pathology ecosystem
You need to be a subscriber to read this article.
Click here to find out more.
Analysis
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)

Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)

As biologics become increasingly complex, demonstrating consistent biological activity at lot release is essential. Yet the cell-based assays used to measure potency introduce significant challenges in standardisation, reproducibility and regulatory compliance
Subscribe now